Lipoprotein(a)

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Synonym(s)

Lp(a)

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Lipoprotein (a) belongs to the plasma lipoproteins and has a largely similar structure to low density lipoprotein (LDL). Lipoprotein(a) has two apolipoproteins:

  • Apolipoprotein B-100, which also occurs as a protein component in LDL and VLDL
  • and
  • Apolipoprotein(a).

Apolipoprotein (a) is very similar to plasminogen. It is assumed that this structural similarity leads to interactions of lipoprotein(a) with fibrinolysis.

General informationThis section has been translated automatically.

Lipoprotein(a) is synthesized in the liver. It has a half-life in the circulation of 3-4 days. The individual plasma value is genetically determined. Concentrations of Lp(a) < 20 mg/dl are considered normal, > 30 mg/dl as safely elevated.

Lp(a) concentrations >30mg/dl are considered an independent atherosclerotic risk factor. Lp(a) increases the expression of plasminogen activator inhibitor-1, which probably inhibits local fibrinolysis.

The therapeutic influence of increased Lp(a) levels is limited. Only nicotinic acid, mainly in combination with statins, can lead to a clinically relevant reduction.

In this respect, it is of particular importance for affected patients to consistently treat cardiovascular risk factors.

Authors

Last updated on: 29.10.2020